Last update 10 May 2025

PectaSol-C Modified Citrus Pectin

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms-
Target
galectin-3
Action
inhibitors
Mechanism
galectin-3 inhibitors(Galectin-3 inhibitors)
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication-
Inactive Indication
Non-metastatic prostate cancer
Originator Organization
EcoNugenics, Inc.EcoNugenics, Inc.
Active Organization-
Inactive Organization
EcoNugenics, Inc.EcoNugenics, Inc.
License Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with PectaSol-C Modified Citrus Pectin
NCT01681823
/ CompletedPhase 2
Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA
100 Clinical Results associated with PectaSol-C Modified Citrus Pectin
Login to view more data
100 Translational Medicine associated with PectaSol-C Modified Citrus Pectin
Login to view more data
100 Patents (Medical) associated with PectaSol-C Modified Citrus Pectin
Login to view more data
100 Deals associated with PectaSol-C Modified Citrus Pectin
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-metastatic prostate cancerPhase 2
Israel
EcoNugenics, Inc.EcoNugenics, Inc.
01 Jun 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01681823 (ASCO_GU2023)
ManualManual
Phase 2
Non-metastatic prostate cancer
59
micxkoifyl(bwewidqyvh) = mhqeepcexh pvcgykebuz (fmeqhrkkpe )
View more
Positive
21 Feb 2023
NCT01681823 (ASCO2019)
Phase 2
Non-metastatic prostate cancer
53
xlstpsbfef(pfqocoozns) = DP at 6 mos was noted in 24% (n = 11: PSA only in 20%, n = 9; PSA and scans in 4%, n = 2) bdlkcadowx (qstfftbkfx )
View more
Positive
26 May 2019
Placebo
NCT01681823 (ASCO2017)
Phase 2
Non-metastatic prostate cancer
35
kwnzbrsfiz(qhxntqsbxu) = 18% (n = 6) had grade 1 toxicity lhfqgrjgkc (mrzzqitdbh )
View more
Positive
30 May 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free